Literature DB >> 20108048

Factors determining utility measured with the EQ-5D in patients with atrial fibrillation.

Jenny Berg1, Peter Lindgren, Robby Nieuwlaat, Olivier Bouin, Harry Crijns.   

Abstract

PURPOSE: Although atrial fibrillation (AF) is associated with increased morbidity and mortality from heart failure, stroke and other thromboembolic complications, there are limited data on its health-related quality of life (HRQoL) effects. The objective was to analyse the factors determining utility in patients with all types of AF, both at baseline and after 1 year from inclusion, based on data from the Euro heart survey.
METHODS: HRQoL was measured with the EQ-5D questionnaire. At baseline, 5,050 patients had completed all five dimensions of the EQ-5D and 3,045 had done so after 1 year. We used Powell's censored least absolute deviations estimator for inference and ordinary least squares regressions for prediction.
RESULTS: Regardless of time point, utility and change in utility were significantly correlated with age, gender, AF type and symptoms. At baseline, utility was also determined by domestic status, regular exercise habits, diabetic disease and comorbidities. At follow-up, additional determinants included underlying heart disease and utility at baseline, and adverse events.
CONCLUSION: Utility in patients with AF and change over time are influenced by demographic and disease-specific variables. Our results can provide useful information on the effect of AF on QoL and input for economic evaluations.

Entities:  

Mesh:

Year:  2010        PMID: 20108048     DOI: 10.1007/s11136-010-9591-y

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  22 in total

Review 1.  Bayesian extensions of the Tobit model for analyzing measures of health status.

Authors:  Peter C Austin
Journal:  Med Decis Making       Date:  2002 Mar-Apr       Impact factor: 2.583

2.  The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy.

Authors:  P Dorian; W Jung; D Newman; M Paquette; K Wood; G M Ayers; J Camm; M Akhtar; B Luderitz
Journal:  J Am Coll Cardiol       Date:  2000-10       Impact factor: 24.094

Review 3.  EuroQol: the current state of play.

Authors:  R Brooks
Journal:  Health Policy       Date:  1996-07       Impact factor: 2.980

4.  Preference-Based EQ-5D index scores for chronic conditions in the United States.

Authors:  Patrick W Sullivan; Vahram Ghushchyan
Journal:  Med Decis Making       Date:  2006 Jul-Aug       Impact factor: 2.583

5.  Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample.

Authors:  Patrick W Sullivan; Vahram Ghushchyan
Journal:  Med Decis Making       Date:  2006 Jul-Aug       Impact factor: 2.583

6.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

7.  Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.

Authors:  Louise S Jenkins; Michael Brodsky; Eleanor Schron; Mina Chung; Thomas Rocco; Ellis Lader; Martha Constantine; Robert Sheppard; Donald Holmes; Donna Mateski; Liz Floden; Marilyn Prasun; H Leon Greene; Lynn Shemanski
Journal:  Am Heart J       Date:  2005-01       Impact factor: 4.749

8.  Quality of life in patients with paroxysmal atrial fibrillation and its predictors: importance of the autonomic nervous system.

Authors:  M P van den Berg; R J Hassink; A E Tuinenburg; E F van Sonderen; J D Lefrandt; P J de Kam; I C van Gelder; A J Smit; R Sanderman; H J Crijns
Journal:  Eur Heart J       Date:  2001-02       Impact factor: 29.983

9.  Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease.

Authors:  I-Chan Huang; Constantine Frangakis; Mark J Atkinson; Richard J Willke; Walter L Leite; W Bruce Vogel; Albert W Wu
Journal:  Health Serv Res       Date:  2008-02       Impact factor: 3.402

10.  Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).

Authors:  Philip Clarke; Alastair Gray; Rury Holman
Journal:  Med Decis Making       Date:  2002 Jul-Aug       Impact factor: 2.583

View more
  20 in total

1.  Economic Evaluation of Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure With Reduced Ejection Fraction.

Authors:  Derek S Chew; Zak Loring; Jatin Anand; Marat Fudim; Angela Lowenstern; Jennifer A Rymer; Kristin E D Weimer; Brett D Atwater; Adam D DeVore; Derek V Exner; Peter A Noseworthy; Clyde W Yancy; Daniel B Mark; Jonathan P Piccini
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-12-07

2.  Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluation.

Authors:  Rui Duarte; Angela Stainthorpe; Janette Greenhalgh; Marty Richardson; Sarah Nevitt; James Mahon; Eleanor Kotas; Angela Boland; Howard Thom; Tom Marshall; Mark Hall; Yemisi Takwoingi
Journal:  Health Technol Assess       Date:  2020-01       Impact factor: 4.014

3.  The Cost of Thromboembolic Events and their Prevention among Patients with Atrial Fibrillation.

Authors:  Thomas Davidson; Magnus Husberg; Magnus Janzon; Lars-Åke Levin
Journal:  J Atr Fibrillation       Date:  2011-02-22

4.  Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland.

Authors:  Jonas Nilsson; Örjan Åkerborg; Gaëlle Bégo-Le Bagousse; Mårten Rosenquist; Peter Lindgren
Journal:  Eur J Health Econ       Date:  2012-05-03

5.  Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke: a systematic review and economic evaluation.

Authors:  Steven J Edwards; Victoria Wakefield; Tracey Jhita; Kayleigh Kew; Peter Cain; Gemma Marceniuk
Journal:  Health Technol Assess       Date:  2020-01       Impact factor: 4.014

6.  Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.

Authors:  Torbjørn Wisløff; Gunhild Hagen; Marianne Klemp
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

7.  Cost-effectiveness of dronedarone and standard of care compared with standard of care alone: US results of an ATHENA lifetime model.

Authors:  Matthew R Reynolds; Jonas Nilsson; Orjan Akerborg; Mehul Jhaveri; Peter Lindgren
Journal:  Clinicoecon Outcomes Res       Date:  2013-01-08

8.  Detecting and Diagnosing Atrial Fibrillation (D2AF): study protocol for a cluster randomised controlled trial.

Authors:  Steven B Uittenbogaart; Nicole Verbiest-van Gurp; Petra M G Erkens; Wim A M Lucassen; J André Knottnerus; Bjorn Winkens; Henk C P M van Weert; Henri E J H Stoffers
Journal:  Trials       Date:  2015-10-23       Impact factor: 2.279

9.  Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece.

Authors:  Georgia Kourlaba; Nikos Maniadakis; George Andrikopoulos; Panos Vardas
Journal:  Cost Eff Resour Alloc       Date:  2014-02-10

10.  The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification.

Authors:  Gareth J Wynn; Derick M Todd; Matthew Webber; Laura Bonnett; James McShane; Paulus Kirchhof; Dhiraj Gupta
Journal:  Europace       Date:  2014-02-16       Impact factor: 5.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.